UPM Biomedicals has signed an extensive distribution agreement for GrowInk bioinks with Brinter Inc, a Finnish-US medtech/biotech company focusing on the development of cartilage implants using their patented 3D bioprinting technology.
UPM Biomedicals’ GrowInks are animal free, biocompatible, and ready-to-use hydrogels that can be mixed directly with cells for bioprinting applications. The two main components in GrowInks are nanofibrillar cellulose and water, providing a fully defined matrix for living cells to grow in. The bioinks can be customised by the addition of molecules, such as growth factors or adhesion proteins, or other biomaterials to customise the cell culture matrix for the specific needs of different cell types.
Ready-to-use and customisable GrowInks mimic the in vivo environment supporting cell growth and differentiation. Over 150 different cell types have been cultured in nanofibrillar cellulose. They can easily be diluted to provide a wide range of stiffnesses that can be matched to the requirements of cells. GrowInks are room temperature stable, and they can be used with or without a crosslinking agent depending on the application. GrowInks enable cell printing layer-by-layer with high-precision cell positioning.
UPM Biomedicals is the forerunner in producing high quality (ISO13485) nanofibrillar cellulose for life science and medical applications. The nanofibrillar cellulose (NFC) can be used in numerous forms and acts as an underlying building block for bridging the worlds of biomaterials, biomanufacturing and medicine.
UPM Biomedicals makes products for life science and clinical uses based on its patented nanofibrillar cellulose technology from birch wood pulp.
